Evotec stock trades close to 52-week low as Q2 revenue declines
Published on 08/22/2026 at 06:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Evotec (ISIN DE0005664809) stock has been trading under sustained pressure in August 2026, with the share price on Xetra at EUR3.32 in intraday trading on August 22, 2026 and only a small margin above its recent 52-week low.
Recent market commentary from August 21, 2026 highlighted that the stock closed at EUR3.39, placing it 33 percent below its 200-day moving average of EUR5.06 and just EUR0.20 above the 52-week low of EUR3.19, underscoring how far sentiment has weakened this year.
At the same time, investors are digesting second quarter 2026 results that showed a clear revenue setback and contributed to a first half loss, reinforcing concerns about profitability and growth momentum.
Q2 2026 revenue decline weighs on outlook
According to a detailed results summary published on August 21, 2026, Evotec reported that revenue in the second quarter 2026 fell by 16.21 percent to EUR143.48 million compared with the same period a year earlier Q2 2026 revenue overview.
The same report noted that the share price during the reaction phase traded at EUR3.34, very close to the 52-week low of EUR3.19 that was reached in mid-July 2026, while the 52-week high of EUR7.75 from November 2025 remains far above the current level.
This combination of a mid-teens percentage revenue decline and a share price that is 56 percent below the 52-week high underlines that the market is adjusting expectations for Evotec after a period of stronger growth.
Shares trade just above 52-week low
Market data as of August 21, 2026 showed Evotec stock at EUR3.39 on Xetra, which was only EUR0.20 higher than the 52-week low of EUR3.19 and placed the shares 33 percent below the 200-day moving average of EUR5.06 Evotec stock near 52-week low.
Intraday on August 22, 2026, real-time data from a German market portal indicated a last Xetra price of EUR3.32, down 1.07 percent from the previous close of EUR3.36, with trading volume of 103,577 shares at 3:05 p.m. local time Evotec intraday quote.
Another trading update from August 21, 2026 recorded that the stock changed hands at EUR3.32 at 4:28 p.m. local time, with an intraday low of EUR3.31 and an opening level of EUR3.36, illustrating how the shares have been drifting lower over recent sessions.
ADR price action on Nasdaq
Evotec is also present in the United States through an American depositary receipt, and recent US trading has mirrored the weakness seen in Frankfurt.
A same-day US market report on August 21, 2026 stated that the ADR had previously closed at $1.96 but opened the next session at $1.9191, with last trades at $1.92 on volume of 4,361 ADRs, signaling limited but clearly negative investor interest in the US venue Evotec ADR gap-down move.
The gap down from $1.96 to an opening level below $1.92 ties in with the broader narrative of Evotec stock trading close to its 52-week low in Europe, meaning that cross-border investors are reacting consistently to the recent financial results and guidance signals.
Drug discovery partnerships as core business
Evotec's core business model centers on providing drug discovery and development services to pharmaceutical and biotechnology partners, spanning early target identification through to preclinical and clinical support across multiple therapeutic areas.
The company typically structures its collaborations with a combination of research payments, milestones, and potential royalty streams, meaning that near-term revenue can fluctuate depending on project timing while long-term value creation is tied to the success of partners' pipelines.
Evotec stock valuation and market context
From a valuation perspective, the key figures currently shaping the discussion are the 16.21 percent year-over-year revenue decline in the second quarter 2026 to EUR143.48 million and the fact that the share price is 56 percent below the 52-week high of EUR7.75, while sitting just EUR0.20 above the 52-week low of EUR3.19.
These numbers suggest that the market is pricing in both the recent setback in reported revenue and the risk that profitability remains under pressure after the company moved into a first half loss, as referenced in recent corporate commentary documenting the financial performance.
For investors, the immediate question is whether Evotec can stabilize revenue in the coming quarters and rebuild confidence, which would be reflected in a recovery of the stock toward its 200-day moving average of EUR5.06 and a narrowing of the gap to the historical high of EUR7.75.
Read more
Investor relations information on Evotec
Selected collaboration example
As a representative example of Evotec's activities, the company has repeatedly highlighted multi-year discovery alliances in which it applies its platform capabilities in areas such as small-molecule discovery and biologics to support partners in advancing candidates toward the clinic.
Such collaborations underscore how Evotec's long-term value is tied not only to quarter-by-quarter revenue from services, but also to scientific execution and the progression of partner pipelines that can generate milestone and royalty income in future years.
Evotec stock price snapshot
As of August 22, 2026, Evotec stock on Xetra was quoted at EUR3.32 in intraday trading, compared with a previous close of EUR3.36 and a 52-week range from EUR3.19 to EUR7.75, highlighting both the recent pressure and the potential upside if fundamentals improve.
Fact box
Company: Evotec SE
ISIN: DE0005664809
Ticker: EVT
Exchange: Xetra
Price (as of August 22, 2026, 3:05 p.m. local time): EUR3.32
Sector / Industry: Biotechnology / Drug discovery services
